Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) FCF Margin (2020 - 2025)

Historic FCF Margin for Neuroone Medical Technologies (NMTC) over the last 11 years, with Q4 2025 value amounting to 109.13%.

  • Neuroone Medical Technologies' FCF Margin fell 1147300.0% to 109.13% in Q4 2025 from the same period last year, while for Dec 2025 it was 71.28%, marking a year-over-year increase of 522500.0%. This contributed to the annual value of 32.09% for FY2025, which is 2903000.0% up from last year.
  • Neuroone Medical Technologies' FCF Margin amounted to 109.13% in Q4 2025, which was down 1147300.0% from 56.05% recorded in Q3 2025.
  • In the past 5 years, Neuroone Medical Technologies' FCF Margin registered a high of 1383.43% during Q3 2022, and its lowest value of 13047.53% during Q1 2021.
  • Over the past 5 years, Neuroone Medical Technologies' median FCF Margin value was 444.0% (recorded in 2023), while the average stood at 2706.36%.
  • In the last 5 years, Neuroone Medical Technologies' FCF Margin tumbled by -54566300bps in 2021 and then skyrocketed by 82615600bps in 2023.
  • Neuroone Medical Technologies' FCF Margin (Quarter) stood at 8120.86% in 2021, then soared by 62bps to 3057.95% in 2022, then soared by 87bps to 393.45% in 2023, then surged by 101bps to 5.61% in 2024, then plummeted by -2046bps to 109.13% in 2025.
  • Its FCF Margin was 109.13% in Q4 2025, compared to 56.05% in Q3 2025 and 86.29% in Q2 2025.